Efficacy and Safety of Lorundrostat Alone, and in Combination With Dapagliflozin in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria - Trial NCT06150924
Access comprehensive clinical trial information for NCT06150924 through Pure Global AI's free database. This Phase 2 trial is sponsored by Mineralys Therapeutics Inc. and is currently Not yet recruiting. The study focuses on Chronic Kidney Disease. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Mineralys Therapeutics Inc.
Timeline & Enrollment
Phase 2
Dec 01, 2023
Jan 01, 2025
Primary Outcome
Part A: Change from baseline in automated office blood pressure (AOBP) SBP at Week 8,Part B: Incidence and severity of AEs
Summary
This is a 2-part study evaluating the efficacy and safety of lorundrostat (an aldosterone
 synthase inhibitor [ASI]) for the treatment of hypertension in subjects with CKD and
 albuminuria while receiving stable treatment with an angiotensin converting enzyme inhibitor
 (ACEi) or an angiotensin receptor blocker (ARB) either in combination with dapagliflozin, or
 alone.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06150924
Non-Device Trial